• Fresenius Terminates $4.3-Billion Merger with Akron americanpharmaceuticalreview
    May 18, 2018
    Fresenius Kabi has decided to terminate the company’s previously announced merger agreement with Akorn, a United States-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products.
PharmaSources Customer Service